These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6491874)

  • 41. Development of a bioassay for anti tumor activity of biological response modifiers of the reticuloendothelial stimulant class: reproducibility of the bioassay.
    Proctor JW; Yamamura Y; DiLuzio NR; Mansell PW
    J Immunopharmacol; 1981-1982; 3(3-4):385-95. PubMed ID: 6752286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of hepatic drug metabolism in the rat after Corynebacterium parvum treatment.
    Farquhar D; Benvenuto JA; Kuttesch N; Loo TL
    Biochem Pharmacol; 1983 Apr; 32(7):1275-80. PubMed ID: 6847717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Gram-positive bacteria as adjuvants (author's transl)].
    Hahn H
    Immun Infekt; 1978 Jun; 6(3):123-6. PubMed ID: 96006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. V. Comparison of the effects of tilorone hydrochloride, levamisole, methanol-soluble fraction of Mycobacterium butyricum, BCG, and a nonviable aqueous ether extract of Brucella abortus preparation in treatment of mice with tumors.
    Fisher B; Linta J; Hanlon J; Saffer E
    J Natl Cancer Inst; 1978 Feb; 60(2):391-9. PubMed ID: 413929
    [No Abstract]   [Full Text] [Related]  

  • 45. Biological effects of Corynebacterium parvum. 3. Amplification of resistance and impairment of active immunity to murine tumours.
    Smith SE; Scott MT
    Br J Cancer; 1972 Oct; 26(5):361-7. PubMed ID: 4343677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Corynebacterium parvum, methanol-extraction residue of BCG, and levamisole on macrophage random migration, chemotaxis, and pinocytosis.
    Sher NA; Poplack DG; Blaese RM; Brown TM; Chaparas SD
    J Natl Cancer Inst; 1977 Jun; 58(6):1753-7. PubMed ID: 864753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Corynebacterium parvum: effects on the biochemistry of mouse serum and liver.
    Green S; Dobrjansky A
    J Natl Cancer Inst; 1979 Aug; 63(2):497-502. PubMed ID: 379402
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparison of the potentiation of specific tumor immunity in mice by Corynebacterium parvum or BCG.
    Scott MT; Bomford R
    J Natl Cancer Inst; 1976 Sep; 57(3):555-9. PubMed ID: 978769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon production by Corynebacterium parvum and BCG-activated murine spleen macrophages.
    Neumann C; Macher E; Sorg C
    Immunobiology; 1980 Apr; 157(1):12-23. PubMed ID: 6162779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin].
    Matsuoka H; Yano K; Baba H; Kounoe S; Seo Y; Saito T; Tomoda H; Wakasugi H
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1644-6. PubMed ID: 7574783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of macrophages in the adjuvant effect on antibody production of Corynebacterium parvum.
    Watson SR; Sljivić VS
    Clin Exp Immunol; 1976 Jan; 23(1):149-53. PubMed ID: 770033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proceedings: The effect of Bacille Calmette-Guérin (BCG) and Corynebacterium parvum on the development of spontaneous mouse mammary carcinoma.
    Simpson JS; Clark AW
    Br J Surg; 1976 Feb; 63(2):152-3. PubMed ID: 766891
    [No Abstract]   [Full Text] [Related]  

  • 53. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury.
    Harbrecht BG; Billiar TR; Stadler J; Demetris AJ; Ochoa J; Curran RD; Simmons RL
    J Leukoc Biol; 1992 Oct; 52(4):390-4. PubMed ID: 1328440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of suppressor mechanisms in allergic contact dermatitis: 2. Inhibition of suppressor T-lymphocytes by Corynebacterium parvum.
    Knop J; Riechmann R; Macher E
    J Invest Dermatol; 1981 May; 76(5):396-9. PubMed ID: 6453168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental nonspecific immunostimulation by the Propionibacterium acnes vaccine.
    Koukalová D; Kod'ousek R; Hájek V; Kolár M
    Acta Univ Palacki Olomuc Fac Med; 1992; 133():19-23. PubMed ID: 1344592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the effect of viral paramunity inducers PIND-AVI and PIND-ORF with that of BCG, Corynebacterium parvum and levamisole on the growth of radiation-induced murine osteosarcoma.
    Müller-Brunecker G; Erfle V; Mayr A
    Zentralbl Veterinarmed B; 1986 Apr; 33(3):188-95. PubMed ID: 3463079
    [No Abstract]   [Full Text] [Related]  

  • 59. The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation.
    Sljivić VS; Watson SR
    J Exp Med; 1977 Jan; 145(1):45-57. PubMed ID: 299769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy.
    Mathé G; Florentin I; Olsson L; Bruley-Rosset M; Schulz J; Kiger N; Orbach-Arbouys S; Schwarzenberg L; Pouillart P; de Vassal F
    Cancer Treat Rep; 1978 Nov; 62(11):1613-21. PubMed ID: 103616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.